Representative Matters
代表事项
REFERENZMANDATE
Public Offerings
- Fusion Pharmaceuticals in its $212.5 million initial public offering
- Moderna Therapeutics in its $604 million initial public offering; $500 million follow-on offering; and $1.34 million follow-on offering
- Black Diamond Therapeutics in its $231.3 million initial public offering
- Xeris Pharmaceuticals in its concurrent $89.3 million offering of common stock and convertible senior notes
- Immatics, N.V. in its ~$1 billion business combination with ARYA Sciences Acquisition Corp. and listing on Nasdaq
- BridgeBio Pharma in its $372.7 million initial public offering
- Ascentage Pharma in its $61 million initial public offering on the HKSE
- Avadel Pharmaceuticals in its $65 million financing transaction and its $125 million follow-on public offering
- BeiGene in the sale of $2.8 billion of shares to Amgen
- Orchard Therapeutics in its $225 million initial public offering
- AquaVenture Holdings in its $117 million initial public offering
- Intellia Therapeutics in its $108 million initial public offering
- CRISPR Therapeutics in its $56 million initial public offering and its $200 million follow-on offering
Convertible Notes
- Inseego Corp. in its offering of $100 million in convertible senior notes
- Cerence, Inc. in its offering of $175 million in convertible senior notes
- HubSpot, Inc. in its offering of $460 million in convertible senior notes
- Health Catalyst in its offering of $200 million in convertible senior notes
- Model N, Inc. in its offering of $150 million in convertible senior notes
- Everbridge, Inc. in its offering of $450 million in convertible senior notes
- Slack Technologies in its offering of $750 million in convertible senior notes
- RingCentral in its offering of $1 billion in convertible senior notes
- Zendesk in its offering of $1.15 billion in convertible senior notes
- Otka in its offering of $1 billion in convertible senior notes
- Varonis Systems in its offering of $220 million in convertible senior notes
- 2U, Inc. in its offering of $380 million in convertible senior notes
Private Financings
- Thrive Earlier Detection Corp. in its $110 million Series A financing and Galecto in its $40 million Series C financing
- Cullinan Oncology in its $100 million Series B financing
- ElevateBio in its $170 million Series B financing
- Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
- Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
- Nimbus Therapeutics in its $43 million Series B financing and $65 million Series C financing
- Scholar Rock in its $36 million Series B financing and $47 million Series C financing
- Cullinan Oncology in its $150 million Series A financing
- Kymera Therapeutics in its $30 million Series A financing
- Ginkgo Bioworks in its agreement with Bayer to launch JoynBio for $100 million Series A investment
Strategic Collaborations and M&A
- Moderna in its strategic collaboration with Lonza Ltd.
- Alnylam Pharmaceuticals in its $2 billion strategic collaboration with Blackstone; and in its development and commercialization collaboration with Dicerna Pharmaceuticals
- Promedior, Inc in its ~$1 billion definitive merger agreement with Roche
- Yantriks in its sale to Blue Yonder Group
- AquaVenture in its $1.1 billion sale to Culligan
- Backstone Life Sciences in its collaboration with Ferring Pharmaceuticals for $570 million
- Semma Therapeutics in its $950 million sale to Vertex Pharmaceuticals
- BlueRock Therapeutics in its $1 billion sale to Bayer AG
- CRISPR Therapeutics in its strategic transaction with Bayer HealthCare to form Casebia Therapeutics; and subsequently in connection to the unwind of Casebia Therapeutics
- Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
- Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
- Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion, and subsequent $2.2 billion merger with Roche
- Quartet Medicine in its $595 million strategic collaboration with Merck
- Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time and strategic alliance with Celgene Corporation in immunology
- CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
- Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
- F-star Alpha in its agreement with Bristol-Myers Squibb
- Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics
- Warp Drive Bio in its acquisition by Revolution Medicines
- Sage Therapeutics in its collaboration with Shionogi for $90 million up front and potential deal value in excess of $575 million
- Pairwise Plants in its collaboration with Monsanto to advance agriculture research and development by leveraging gene editing technology for $100 million
- Alnylam Pharmaceuticals on its strategic restructuring of its RNAi therapeutics alliance with Sanofi
